Thanks for the info on that. It looks like they'll repeat the study using a different treatment sequence, learn from it, and then move forward on the indication guided by the new observations

We'll see if they decide to move forward with the pilot study this summer after the redo of the preclinical study

I'll bet the company is also looking at whether PD-L1 is raised as well

Go long